An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

The higher the dosage of cholesterol-lowering statins, the greater a patient’s risk of developing osteoporosis, according to work published in the Annals of Rheumatic Diseases.

CVS Pharmacy announced Sept. 28 it would be suspending the sales of all Zantac-brand and CVS Health-brand ranitidine products until further notice, pending the results of an FDA investigation.

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

Frequent and persistent hot flashes during menopause can majorly raise women’s risk of clinical CVD events in the following 20 years, researchers reported at the 30th Annual Meeting of the North American Menopause Society.

Medtronic announced Sept. 27 that it had received FDA approval to launch an early feasibility study for its Intrepid TMVR system using a minimally invasive transfemoral access approach.

Tests commissioned by NBC News have revealed that vitamin E—the suspected culprit behind some 800-plus reported cases of vaping-related lung illness—is present in many THC cartridges sold on the black market, alongside other toxicities like pesticides and myclobutanil.

A shortened, three-month course of dual antiplatelet therapy might be a safer bet than 12-month treatment for patients at a high risk of bleeding after PCI and implantation of a drug-eluting stent.